JP2019518022A5 - - Google Patents

Download PDF

Info

Publication number
JP2019518022A5
JP2019518022A5 JP2018562567A JP2018562567A JP2019518022A5 JP 2019518022 A5 JP2019518022 A5 JP 2019518022A5 JP 2018562567 A JP2018562567 A JP 2018562567A JP 2018562567 A JP2018562567 A JP 2018562567A JP 2019518022 A5 JP2019518022 A5 JP 2019518022A5
Authority
JP
Japan
Prior art keywords
compound
intrahepatic cholestasis
ceradelpar
amount
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018562567A
Other languages
Japanese (ja)
Other versions
JP2019518022A (en
JP7079735B2 (en
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/029620 external-priority patent/WO2017209865A1/en
Publication of JP2019518022A publication Critical patent/JP2019518022A/en
Publication of JP2019518022A5 publication Critical patent/JP2019518022A5/ja
Application granted granted Critical
Publication of JP7079735B2 publication Critical patent/JP7079735B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (18)

肝内胆汁うっ滞性疾患の処置用の医薬であって、セラデルパル(Seladelpar)またはその塩である化合物を、5mg/日または10mg/日のセラデルパルに相当する量で含む、医薬。   A medicament for the treatment of intrahepatic cholestasis, which comprises a compound of Seladelpar or a salt thereof in an amount corresponding to 5 mg / day or 10 mg / day of Celadelpar. 前記化合物が、セラデルパルのL-リシン塩である、請求項1に記載の医薬。   The drug according to claim 1, wherein the compound is an L-lysine salt of ceradelpar. 前記化合物が、セラデルパルL-リシン二水和物である、請求項2に記載の医薬。   The medicine according to claim 2, wherein the compound is ceradelpar L-lysine dihydrate. 1日1回投与である、請求項1〜3のいずれか一項に記載の医薬。   The medicine according to any one of claims 1 to 3, which is administered once a day. 前記化合物の量が、5mg/日のセラデルパルに相当する量である、請求項4に記載の医薬。   The medicine according to claim 4, wherein the amount of the compound is an amount corresponding to 5 mg / day of ceradelpal. 前記化合物の量が、10mg/日のセラデルパルに相当する量である、請求項4に記載の医薬。   The medicine according to claim 4, wherein the amount of the compound is an amount corresponding to 10 mg / day of ceradelpal. 肝内胆汁うっ滞性疾患が、原発性胆汁性胆管炎、原発性硬化性胆管炎、進行性家族性肝内胆汁うっ滞またはアラジール症候群である、請求項1〜6のいずれか一項に記載の医薬。   The intrahepatic cholestasis disease is primary bile cholangitis, primary sclerosing cholangitis, progressive familial intrahepatic cholestasis or Alagille syndrome, according to any one of claims 1 to 6. Medicine. 肝内胆汁うっ滞性疾患が原発性胆汁性胆管炎である、請求項7に記載の医薬。   The drug according to claim 7, wherein the intrahepatic cholestasis is primary cholangitis. 肝内胆汁うっ滞性疾患が原発性硬化性胆管炎である、請求項7に記載の医薬。   The medicine according to claim 7, wherein the intrahepatic cholestasis is primary sclerosing cholangitis. 肝内胆汁うっ滞性疾患が進行性家族性肝内胆汁うっ滞である、請求項7に記載の医薬。   The medicament according to claim 7, wherein the intrahepatic cholestasis is progressive familial intrahepatic cholestasis. 肝内胆汁うっ滞性疾患がアラジール症候群である、請求項7に記載の医薬。   The medicine according to claim 7, wherein the intrahepatic cholestasis is Alagille syndrome. 経口投与用の、請求項1〜11のいずれか一項に記載の医薬。   The medicament according to any one of claims 1 to 11, for oral administration. セラデルパルまたはその塩である化合物を、5mgまたは10mgのセラデルパルに相当する量で含む、経口薬。   An oral drug comprising a compound which is ceradelpar or a salt thereof in an amount corresponding to 5 mg or 10 mg of ceradelpar. 前記化合物が、セラデルパルのL-リシン塩である、請求項13に記載の経口薬。   The oral drug according to claim 13, wherein the compound is an L-lysine salt of ceradelpar. 前記化合物が、セラデルパルL-リシン二水和物である、請求項14に記載の経口薬。   The oral drug according to claim 14, wherein the compound is ceradelpar L-lysine dihydrate. 前記化合物の量が、5mgのセラデルパルに相当する量である、請求項13〜15のいずれか一項に記載の経口薬。   The oral drug according to any one of claims 13 to 15, wherein the amount of the compound is an amount corresponding to 5 mg of ceradelpal. 前記化合物の量が、10mgのセラデルパルに相当する量である、請求項13〜15のいずれか一項に記載の経口薬。   The oral drug according to any one of claims 13 to 15, wherein the amount of the compound is an amount corresponding to 10 mg of ceradelpal. 錠剤またはカプセル剤である、請求項13〜17のいずれか一項に記載の経口薬。   The oral drug according to any one of claims 13 to 17, which is a tablet or capsule.
JP2018562567A 2016-05-31 2017-04-26 Treatment of intrahepatic cholestasis disease Active JP7079735B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662343688P 2016-05-31 2016-05-31
US62/343,688 2016-05-31
PCT/US2017/029620 WO2017209865A1 (en) 2016-05-31 2017-04-26 Treatment of intrahepatic cholestatic diseases

Publications (3)

Publication Number Publication Date
JP2019518022A JP2019518022A (en) 2019-06-27
JP2019518022A5 true JP2019518022A5 (en) 2020-05-21
JP7079735B2 JP7079735B2 (en) 2022-06-02

Family

ID=58699276

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018562567A Active JP7079735B2 (en) 2016-05-31 2017-04-26 Treatment of intrahepatic cholestasis disease

Country Status (25)

Country Link
US (5) US10272058B2 (en)
EP (1) EP3463328B1 (en)
JP (1) JP7079735B2 (en)
KR (1) KR102408288B1 (en)
CN (1) CN109195594A (en)
AU (1) AU2017274293B2 (en)
BR (1) BR112018074147A2 (en)
CA (1) CA3024155C (en)
DK (1) DK3463328T3 (en)
ES (1) ES2921230T3 (en)
HR (1) HRP20220903T1 (en)
HU (1) HUE059838T2 (en)
IL (1) IL263372B2 (en)
LT (1) LT3463328T (en)
MX (1) MX2018014915A (en)
NZ (1) NZ748721A (en)
PL (1) PL3463328T3 (en)
PT (1) PT3463328T (en)
RS (1) RS63345B1 (en)
RU (1) RU2765460C2 (en)
SG (1) SG11201810123SA (en)
SI (1) SI3463328T1 (en)
UA (1) UA122719C2 (en)
WO (1) WO2017209865A1 (en)
ZA (1) ZA201808360B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3119384B1 (en) 2014-03-20 2018-09-12 CymaBay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
AU2019378845A1 (en) * 2018-11-16 2021-06-03 Cymabay Therapeutics, Inc. Combination treatment of NAFLD and NASH
RS65546B1 (en) * 2021-02-01 2024-06-28 Cymabay Therapeutics Inc Treatment of cholangiopathies with seladelpar

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101993B1 (en) 1990-01-11 2006-09-05 Isis Pharmaceuticals, Inc. Oligonucleotides containing 2′-O-modified purines
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US6166197A (en) 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
DE69636160D1 (en) 1995-03-06 2006-06-29 Isis Pharmaceuticals Inc PROCESS FOR SYNTHESIS OF 2'-O-SUBSTITUTED PYRIMIDINES AND OLIGOMERS THEREOF
TR199801581T2 (en) 1996-02-14 1998-10-21 Isis Pharmaceuticals, Inc. �ekerle de�i�tirilmi� bo�luklu oligon�kleotid’ler.
US5883109A (en) 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
US7981915B2 (en) 2003-04-30 2011-07-19 Beth Israel Deaconess Medical Center Methods for modulating PPAR biological activity for the treatment of diseases caused by mutations in the CFTR gene
WO2005042478A2 (en) 2003-09-19 2005-05-12 Janssen Pharmaceutica, N.V. 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
US7932268B2 (en) 2004-03-05 2011-04-26 The Trustees Of The University Of Pennsylvania Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
JO3006B1 (en) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv Novel Lysine Salts of 4-((Phenoxy Alkyl)Thio)-Phenoxy Acetic Acid Derivatives
ES2712052T3 (en) 2008-10-17 2019-05-09 Cymabay Therapeutics Inc Methods to reduce small and dense LDL particles
KR101357438B1 (en) * 2009-04-29 2014-02-06 아마린 코포레이션 피엘씨 Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
CN102834099B (en) 2010-03-30 2015-05-27 诺华有限公司 Uses of DGAT1 inhibitors
JOP20200043A1 (en) 2011-05-10 2017-06-16 Amgen Inc Methods of treating or preventing cholesterol related disorders
US20150139987A1 (en) 2013-11-20 2015-05-21 Cymabay Therapeutics, Inc. Treatment of homozygous familial hypercholesterolemia
US20160279085A1 (en) 2013-11-20 2016-09-29 Cymabay Therapeutics, Inc. Treatment of Severe Hyperlipidemia
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
EP3119384B1 (en) 2014-03-20 2018-09-12 CymaBay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
PT3129018T (en) 2014-04-11 2020-01-15 Cymabay Therapeutics Inc Treatment of nafld and nash
EA201790091A1 (en) 2014-06-26 2017-07-31 Саймабэй Терапьютикс, Инк. TREATMENT OF HEAVY HYPERTRIGLICERIDEMIA
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
JP7023371B2 (en) 2017-09-26 2022-02-21 サイマベイ・セラピューティクス・インコーポレイテッド Treatment of cholestasis pruritus
AU2019378845A1 (en) 2018-11-16 2021-06-03 Cymabay Therapeutics, Inc. Combination treatment of NAFLD and NASH
MX2021005725A (en) 2018-11-16 2021-07-21 Cymabay Therapeutics Inc Treatment of obesity and its complications.

Similar Documents

Publication Publication Date Title
JP2019518022A5 (en)
CY1119886T1 (en) METHOD FOR MANUFACTURING OF A PHARMACEUTICAL COMPOSITION IN FORM OF PROLONGED RELEASE TABLET CONTAINING pirfenidone and uses thereof regression CHRONIC RENAL DEFICIENCY, KAPSIKIS SYSPASIS udder of hepatic INOSIS IN HUMANS
JP2019535760A5 (en) Treatment of Attention Deficit Hyperactivity Disorder (ADHD) with Gaboxador
JP2017506624A5 (en)
JP2015057451A5 (en)
JP2020535225A5 (en)
JP2016034978A5 (en)
JP2015038135A5 (en)
JP2018527392A5 (en)
JP2015187157A5 (en)
JP2017508817A5 (en)
JP2011173928A5 (en)
RU2018146504A (en) Treatment of intrahepatic cholestatic diseases
JP2016185995A5 (en)
JP2012193216A5 (en)
JP2015523407A5 (en)
JP2015512406A5 (en)
JP2013231087A5 (en)
JP2017014206A5 (en)
JP2015522630A5 (en)
JP2019218379A5 (en)
JP2014198723A5 (en)
RU2014141893A (en) APPLICATION OF THE PYRAZOLE DERIVATIVE IN THE TREATMENT OF ACUTE ACTIONS OF CHRONIC OBSTRUCTIVE LUNG DISEASE
JP2015510916A5 (en)
JP2013166781A5 (en)